Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents...
Main Authors: | Marcia L. Moss, Dmitry Minond |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2017/9673537 |
Similar Items
-
ADAM17: An Emerging Therapeutic Target for Lung Cancer
by: Mohamed I. Saad, et al.
Published: (2019-08-01) -
ADAM Metallopeptidase Domain 33 (ADAM33): A Promising Target for Asthma
by: Priya Tripathi, et al.
Published: (2014-01-01) -
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
by: Neele Schumacher, et al.
Published: (2019-11-01) -
Recent Advances in Immunology to Target Cancer, Inflammation and Infections
Published: (2012) -
Leukocyte ADAM17 regulates acute pulmonary inflammation.
by: Patrick G Arndt, et al.
Published: (2011-01-01)